Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic.
K HanselC PatrunoE AntonelliGiacomo Dal BelloMaddalena NapolitanoG FabbrociniT GriecoG PellacaniMaria-Concetta FargnoliM EspositoV PirasM ZuccaG GirolomoniLuca StingeniPublished in: Clinical and experimental dermatology (2021)